retatrutide phase 2 results 2024 2025 Availability & Timeline Eli Lilly just announced striking

SKU: 87257557217

Pay in 4 interest-free payments of $6.42 Learn more

Live Spec

Eli Lilly just announced striking Phase 3 results for retatrutide, an experimental triple agonist that acts on three gut hormone targets at once. On the top dose, people lost an average of 28% Retatrutide dosage chart for weight loss NiceRx Retatrutide produces up to 30.3% weight loss in Phase 3 trial Triple hormone receptor agonist retatrutide for metabolic dysfunction associated steatotic liver disease: a randomized phase 2a trial Nature Medicine

Store: lifelines-uk.org.uk · Domain: lifelines-uk.org.uk